¿¬¼ö°­ÁÂ
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ : 2021-04-02
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ : 2021-04-02
±³À°ÀÏÀÚ : 2021-04-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ      
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : À±ÁöÇý
¿¬¶ôó : 02-566-6031  
À̸ÞÀÏ : hematology@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í ´ëÇÑÇ÷¾×ÇÐȸ ȸ¿ø £Ü50,000, Æç·Î¿ì/°£È£»ç/¿¬±¸¿ø £Ü30,000 Çлý/Àü°øÀÇ £Ü20,000, ºñȸ¿ø £Ü150,000      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 09:00~09:30 B-Cell Lymphoma''s New Genomics  °í¿µÀÏ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 09:30~10:00 Immuno-Oncology for B-Cell Lymphomas  ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 10:00~10:30 Novel Combination Immunochemotherapy beyond CD20  ÀÌÁØÈ£(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 10:30~11:15 Genetic Landscape of Lymphoma and Novel Treatment Approaches  Wyndham Hopkins Wilson(National Cancer Institute USA) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 11:30~12:10 When and How to Treat Front-Line Chronic Lymphocytic Leukemia?  Susan O¡¯Brien(University of Cambridge USA) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 12:40~13:40 Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma  Á¶Çö¼ö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 13:55~14:40 The Evolution of Acute Leukemia Diagnostics and Its Place in Treatment  Elizabeth Macintyre(The Hôpital Necker-Enfants Malades France) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 14:40~15:10 Outcome of Autologous Transplant in T-Cell Lymphoma: Experience of NIHBT in Vietnam  Nguyen Vu Bao Anh(Hanoi Medical University Vietnam) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 15:10~15:40 Subcutaneous Panniculitis-like T-Cell Lymphoma  Udomsak Bunworasate(King Chulalongkorn Memorial Hospital Thailand) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 15:40~16:10 Update of Extranodal NK/T-cell Lymphoma: Treatment and Biology  ±è¼®Áø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 16:25~16:45 Immunotherapy in AML: From alloSCT towards CAR-T Cell Therapy  Charles Craddock(Queen Elizabeth Hospital UK) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 16:45~17:05 The Emerging Role of MRD in AML  Gert Ossenkoppele(Amsterdam University The Netherlands) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 17:05~17:30 Therapeutic Potential of ATO to Overcome Resistance of Bcl-2 Inhibitor in AML  ÀåÁöÀº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 17:30~17:55 MRD in AML  Á¶º´½Ä(°¡Å縯ÀÇ´ë) 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[Á¦ÁÖ] 2024³â ´ëÇѳúÁ¹ÁßÇÐȸ Ãá°èÇмú´ëȸ : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ Á¦ÁÖ ±³À°ÁÖÁ¦ : 2024³â ´ëÇѳúÁ¹ÁßÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ´ã´çÀÚ : ±èÈñ¿µ ¿¬¶ôó : 0502-27

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,486 , ´ñ±Û¼ö : 0

[¼­¿ï] 2024³â Á¦11ȸ °­µ¿°æÈñ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾ö : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : °­µ¿°æÈñ´ëÇб³º´¿ø º°°üµ¿ 4Ãþ Â÷ÈÄ¿µÈ¦ ±³À°ÁÖÁ¦ : 2024³â Á¦11ȸ °­µ¿°æÈñ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : °­µ¿°æÈñ´ëÇб³º´¿ø ½Ã

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,324 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) Á¦9ȸ ºñ¸¸Àü¹®°¡ ±âÃÊ°úÁ¤ : 2024-04-28

±³À°ÀÏÀÚ : 2024-04-28 ±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦9ȸ ºñ¸¸Àü¹®°¡ ±âÃÊ°úÁ¤ ÁÖÃÖ±â°ü : ´ëÇѺñ¸¸ÇÐȸ ´ã´çÀÚ : ÃÖÀ±Áö ¿¬¶ôó : 02-6941-087

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,446 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù) : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : ¿Â¶óÀÎ (24½Ã°£ VOD ´çÀÏ ¼ÛÃâ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù)ÁÖÃÖ±â°ü : ¼­¿ïƯ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,478 , ´ñ±Û¼ö : 1

[´ëÀü] 2024 ´ëÇѳ»½Ã°æ·Îº¿¿Ü°úÇÐȸ Ãá°è Çмú´ëȸ ¹× 14ȸ ±¹Á¦½ÉÆ÷Áö¿ò (KSERS 2024)(1ÀÏÂ÷) : 2024-04-11

±³À°ÀÏÀÚ : 2024-04-11 ±³À°Àå¼Ò : ´ëÀüÄÁº¥¼Ç¼¾ÅÍ Á¦1Àü½ÃÀå ±³À°ÁÖÁ¦ : (¿ÀÇÁ¶óÀÎ)2024 ´ëÇѳ»½Ã°æ·Îº¿¿Ü°úÇÐȸ Ãá°è Çмú´ëȸ ¹× 14ȸ ±¹Á¦½ÉÆ÷Áö¿ò (KSERS 2

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,496 , ´ñ±Û¼ö : 0